BPC-157
A stable gastric pentadecapeptide with extensive preclinical research supporting its role in tissue repair, angiogenesis, and cytoprotection.
Overview
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protective protein found in human gastric juice. It is classified as a stable gastric pentadecapeptide owing to its remarkable stability in highly acidic environments, distinguishing it from many other bioactive peptides.
BPC-157 is one of the most extensively studied peptides in preclinical research, with hundreds of published studies spanning tissue healing, organ protection, and modulation of multiple biological pathways. Its broad spectrum of observed effects has made it a cornerstone compound in tissue regeneration research. The peptide is notably stable in gastric acid, allowing for both injectable and oral routes of administration in research settings.
Mechanism of Action
BPC-157 exhibits a complex, multi-pathway mechanism of action that researchers are still elucidating. Key pathways include:
- Angiogenesis Promotion: BPC-157 has been observed to significantly upregulate VEGF (vascular endothelial growth factor) expression and stimulate the formation of new blood vessels, accelerating tissue perfusion in damaged areas.
- Nitric Oxide System Modulation: Research indicates BPC-157 interacts with the nitric oxide (NO) system, promoting vasodilation and blood flow to injured tissues. It appears to modulate both eNOS and iNOS pathways.
- Growth Factor Upregulation: Studies have demonstrated upregulation of multiple growth factors including EGF, FGF, and their receptors in the presence of BPC-157, supporting accelerated tissue repair cascades.
- FAK-Paxillin Pathway: BPC-157 has been shown to activate the FAK (focal adhesion kinase)-paxillin signaling pathway, which plays a critical role in cell migration, adhesion, and wound healing.
- JAK-2/STAT-3 Signaling: Evidence suggests involvement of the JAK-2/STAT-3 pathway, which is associated with cell proliferation, survival, and anti-inflammatory responses.
- Cytoprotective Properties: BPC-157 demonstrates protective effects against various damaging agents including NSAIDs, alcohol, and other cytotoxic insults, likely through modulation of prostaglandin and dopamine systems.
Key Research Findings
- Tendon and Ligament Healing: Multiple rodent studies have demonstrated accelerated healing of transected Achilles tendons and medial collateral ligaments, with improved biomechanical properties including higher load-to-failure values.
- Gastrointestinal Protection: Extensive research shows BPC-157 exerts potent cytoprotective and healing effects on GI lesions, including gastric ulcers, inflammatory bowel conditions, and esophageal damage in animal models.
- Muscle Healing: Studies in crush injury and transection models of skeletal muscle demonstrated accelerated functional recovery and improved histological outcomes with BPC-157 administration.
- Bone Healing: Animal studies have reported enhanced fracture healing and pseudoarthrosis repair, with improved bone density and callus formation in BPC-157-treated groups.
- Neuroprotective Effects: Research has observed neuroprotective properties in models of traumatic brain injury, peripheral nerve damage, and dopaminergic system disturbances.
Research Applications
- Musculoskeletal Regeneration: Tendon, ligament, muscle, and bone healing research in preclinical injury models.
- Gastroenterology Research: Cytoprotection, ulcer healing, and inflammatory bowel research.
- Wound Healing: Studying angiogenesis, collagen deposition, and tissue remodeling pathways.
- Neuroprotection Research: Investigating protective effects on central and peripheral nervous system models.
- Organ Protection: Studying cytoprotective mechanisms across liver, heart, and kidney injury models.
Dosing Protocols (Research Use Only)
The following dosing information reflects common protocols described in published research literature:
| Parameter | Details |
|---|---|
| Dosage Range (Research) | 200 – 800 mcg per day (injectable); 500 – 1000 mcg per day (oral) |
| Frequency | Once or twice daily |
| Cycle Duration | 4 – 12 weeks commonly observed in research protocols |
| Route | Subcutaneous injection (near site of interest) or oral administration |
| Preclinical Dose (Rodent) | 10 mcg/kg is the most commonly used dose in published animal studies |
This profile is provided for educational and informational purposes only. BPC-157 is sold as a research chemical and is not approved by the FDA for human use. All information presented is based on published research literature and should not be construed as medical advice. Always consult qualified professionals before making any decisions related to peptide research.
Ready to Research BPC-157?
Get ≥99% purity research-grade peptides with COA from Iron Peak Peptides.